[{"id":"f63cdb8b-80b6-404d-814f-9d31ad0e7012","acronym":"2087GCCC","url":"https://clinicaltrials.gov/study/NCT04666649","created_at":"2021-01-19T20:43:47.273Z","updated_at":"2024-07-02T16:35:11.039Z","phase":"Phase 1","brief_title":"Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)","source_id_and_acronym":"NCT04666649 - 2087GCCC","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" TP53 • FLT3 • IDH1","pipe":" | ","alterations":" TP53 mutation • IDH2 mutation","tags":["TP53 • FLT3 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-04-08"}]